Skip to main content

REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1384600
This article is part of the Research Topic Transplantation and Cellular Therapy in Lymphomas and Plasma Cell Disorders View all 9 articles

The Treatment of Follicular Lymphoma with CD-19 Directed Chimeric Antigen Receptor-T Cell Therapy

Provisionally accepted
Ryan Jacobs Ryan Jacobs 1*Caron Jacobson Caron Jacobson 2
  • 1 Levine Cancer Institute, Charlotte, United States
  • 2 Dana–Farber Cancer Institute, Boston, Massachusetts, United States

The final, formatted version of the article will be published soon.

    Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL). Significant unmet need remains for patients with relapsed/refractory (R/R) FL after ≥3 lines of prior therapy. While recent advancements have likely improved the survival of FL patients, most patients will eventually relapse. The treatment of FL patients after multiple relapses or those with refractory disease has historically led to lower overall response rates (ORR) and shorter progression free survival (PFS) with each subsequent line of therapy. New treatments with high ORR and durable PFS are needed in this setting, particularly in patients that progress within 2 years of first line chemoimmunotherapy (POD24) and/or those refractory chemoimmunotherapy. Chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell antigen CD-19 have shown to be an efficacious treatment option for both heavily pretreated and/or refractory FL patients resulting in a high ORR and durable remissions.

    Keywords: Lymphoma, follicular lymphoma, CAR T, Axicabtagene ciloleucel, Tisagenlecleucel (tisa-cel, Kymriah), Lisocabtagene maraleucel, mosunetuzumab

    Received: 09 Feb 2024; Accepted: 29 Apr 2024.

    Copyright: © 2024 Jacobs and Jacobson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ryan Jacobs, Levine Cancer Institute, Charlotte, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.